Quick Answer: CRISPR gene editing uses a guide RNA and the Cas9 enzyme to cut DNA at a chosen location.1 Casgevy, approved by the FDA on 8 December 2023 for sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises, is the first FDA-approved therapy to use CRISPR/Cas9.2 In an Editverse analysis of ClinicalTrials.gov run on 31 October 2026, 194 records matched…
